≥99% HPLCPre-filled pen

VIP (Vasoactive Intestinal Peptide)

Name: VIP (Vasoactive Intestinal Peptide)
Brand: Dripfy
Availability: InStock

What it is?

VIP is a naturally occurring neuropeptide hormone studied for its broad regulatory roles across vascular tone, immune modulation, gastrointestinal function, and neuro-circadian signalling. It is positioned for multi-system protocols where neuroimmune balance and smooth-muscle regulation are core endpoints.

Dripfy Advantage

Receptor engagement: Binds to VIP receptors (commonly VPAC receptor pathways), influencing smooth-muscle relaxation signalling.
Vascular and smooth-muscle modulation: Supports vasodilatory and smooth-muscle relaxation dynamics relevant to circulation and GI motility endpoints.
Immune modulation: Associated with regulation of immune-cell activity and inflammatory signalling balance.
Neuro-circadian interface: Frequently studied for involvement in circadian regulation and neuronal signalling pathways impacting sleep and rhythm stability.

Clinical Applications & Therapeutic Potential

Digestive and motility endpoints: Potential support for gastrointestinal function markers and smooth-muscle regulation outcomes.
Circulatory health frameworks: Potential improvements in vascular tone markers and circulation-related endpoints (context-dependent).
Anti-inflammatory signalling: Positioned for reduced inflammatory response markers and improved immune balance profiles.
Sleep and circadian regulation: Potential support for circadian rhythm stability and sleep-quality endpoints via neuropeptide signalling pathways.

Composition & Formulation

Peptide/Class: VIP neuropeptide (vasoactive / neuroimmune signalling peptide)
Format: Ready-to-use pre-filled pen

€499

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

VIP (Vasoactive Intestinal Peptide)

Neuropeptide immunomodulator (VIP, VPAC receptor agonist) · Pre-filled pen

C· Emerging evidence

VIP (vasoactive intestinal peptide) is a naturally occurring neuropeptide that signals through VPAC receptors to relax smooth muscle and to dampen and rebalance inflammatory and immune activity. In immune contexts it is studied for shifting responses toward a more regulated, anti-inflammatory profile. A synthetic form (aviptadil) has been investigated in respiratory and inflammatory conditions, but the evidence remains investigational.

Studied use areas

Studied for immune modulation and anti-inflammatory signalling balance
Investigated in respiratory and pulmonary inflammatory conditions as the synthetic form aviptadil
Explored for vascular smooth-muscle relaxation and circulation-related endpoints
Examined for neuro-circadian and gastrointestinal-motility signalling roles

Safety & status

Investigational for immune indications; the synthetic form has been trialled but is not an established immune therapy in the EU/UK
Its vasodilatory action can produce flushing and blood-pressure changes, as reported in studies
It is not appropriate for self-directed immune use and requires physician supervision

⚕ Clinical note: This is educational information, not medical advice. VIP is a genuine signalling peptide, but its use for immune purposes is investigational and any benefit remains unproven in that setting. It is not a substitute for established care, and suitability must be assessed and monitored under physician supervision.

Evidence: Grade C — investigational for immune indications; the synthetic form has been trialled but is not an established therapy · References: peer-reviewed neuroimmunology and pulmonary research literature; clinical trial reports on aviptadil (synthetic VIP); reviews of VIP and VPAC receptor pharmacology